-
SAR131675 and VEGFR-3 Signaling in Liver Fibrosis
2026-10-07
SAR131675 is a selective VEGFR-3 inhibitor used in preclinical research on lymphangiogenesis, angiogenesis, tumor biology, and fibrosis. A 2026 Phytomedicine study used SAR131675 alongside hepatocyte-specific Vegfc deletion to investigate how hepatocyte-derived VEGFC influences macrophage recruitment and phenotype in diet-associated liver fibrosis. The findings support a VEGFC–VEGFR-3–CCL2/CCR2 axis, but they remain preclinical and do not establish clinical efficacy, safety, or suitability for human NASH treatment.
-
Tacalcitol Sensitizes CRC Cells to 5-FU via TS
2026-10-06
The reference study shows that tacalcitol, a vitamin D analog, increases the sensitivity of human HT-29 colorectal cancer cells to 5-fluorouracil by activating VDR-linked CDKN1A expression and reducing thymidylate synthase. Its findings provide a mechanistic rationale for combining vitamin D analogs with 5-FU, while remaining limited by the mainly cell-based evidence and the need for clinical validation.
-
Methylprednisolone in Bone and Inflammation Research
2026-10-06
A source-grounded overview of Methylprednisolone as a synthetic glucocorticoid receptor agonist, covering anti-inflammatory research context, glucocorticoid-induced osteonecrosis models, published findings, evidence strength, and translational limitations.
-
Ranolazine and HBV: A Translational Hypothesis
2026-10-05
A source-grounded perspective on how Ranolazine’s cardiac and metabolic pharmacology could inform, but not yet validate, new research questions at the intersection of HBV immune evasion, TBK1 signaling, autophagy, and liver metabolism.
-
Mubritinib (TAK 165): A Mitochondrial Lens
2026-10-04
Mubritinib and TAK 165 are best interpreted through mitochondrial dependency rather than HER2 activity alone. This article connects cancer biology with a cardiac OXPHOS study to clarify evidence strength, translational boundaries, and research questions.
-
MLN8237 (Alisertib): Aurora A Evidence Guide
2026-10-03
MLN8237, also called Alisertib, is a supplier-described selective Aurora A kinase inhibitor for cancer biology research. Product data report nanomolar biochemical potency, while a peer-reviewed aneugenicity study provides a framework for interpreting mitotic-kinase effects without establishing MLN8237-specific activity.
-
Mubritinib (TAK 165): Complex I Workflow
2026-10-02
Mubritinib (TAK 165) is most useful as a mitochondrial complex I and oxidative phosphorylation probe, not simply as a legacy HER2 kinase tool. This workflow connects viability, ROS, mitochondrial potential, apoptosis, and cisplatin-sensitization assays across AML, PEL, and NSCLC models while highlighting practical controls for reproducibility.
-
GPR68 Inhibition, Ferroptosis, and Radiosensitivity
2026-10-01
A 2025 Scientific Reports study identifies GPR68 inhibition as a trigger of ferroptosis and a sensitizer to ionizing radiation in lung and pancreatic cancer cell models. Its experiments connect acidic-tumor-microenvironment signaling with intracellular ferrous iron mobilization, lipid peroxidation, and reduced colony growth in both 2D and 3D cultures.
-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-10-01
Hao et al. developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal–organic framework nanoparticle that combines near-infrared photothermal therapy with PD-1/PD-L1 checkpoint blockade. The study shows how stimulus-responsive release and immune activation can be integrated into one platform while also highlighting the need for quantitative efficacy, safety, and translational studies.
-
Gap26: Decoding Cx43 Inflammation Signaling
2026-09-30
Gap26 is a connexin 43 mimetic peptide for dissecting how Cx43 links intercellular communication with NF-κB-driven inflammation. This guide translates macrophage evidence into practical assay decisions, controls, and cross-domain applications.
-
Cathepsin B inhibitor CA-074: Lab Workflow
2026-09-30
This practical guide explains how to use CA-074 to test cathepsin B-dependent proteolysis in biochemical, cellular, cancer metastasis, neurotoxicity, and immune-response workflows. It is suitable for controlled research assays, but product-dossier findings should not be treated as universal cell potency, clinical evidence, or a substitute for orthogonal target-validation methods.
-
SIRT3-SUMO, N-Glycosylation, and Asthma Tregs
2026-09-29
This study links SIRT3 SUMOylation to Treg differentiation and asthma through fatty acid oxidation, acetyl-CoA availability, and N-glycosylation substrate production. Its combined computational, cellular, molecular, and in vivo design provides a mechanistic framework for understanding how metabolic regulation may influence both Th2 and non-Th2 asthma phenotypes.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-09-29
This 2024 Nature Communications study identifies acetylation-dependent control of the spliceosomal protein SmD2 as a mechanistic link between alternative splicing, DNA-damage repair, and PARP-inhibitor response in hepatocellular carcinoma. The work supports a preclinical strategy combining HDAC-directed intervention with olaparib, particularly in models where conventional PARP-inhibitor sensitivity is limited.
-
Annexin V-Cy5: Reading Apoptosis in Microglia
2026-09-28
Annexin V apoptosis detection can help determine whether microglial dysfunction includes phosphatidylserine exposure—or instead reflects impaired lysosomal processing without cell death. This article develops an interpretation-led workflow grounded in a reversible zebrafish lysosomal-stress study.
-
Isochlorogenic acid A: Hydrogel Research Workflow
2026-09-27
Explore how Isochlorogenic acid A can move from solvent-controlled natural product assays into Fe(III)-coassembled hydrogel studies. A recent wound-repair study offers useful formulation and assay benchmarks, while this workflow separates reported findings from practical starting conditions that require local optimization.